Exelon Patch

Exelon Patch Use In Pregnancy & Lactation





Full Prescribing Info
Use In Pregnancy & Lactation
Women of child-bearing potential: There is no information available on the effects of rivastigmine in women of child-bearing potential.
Pregnancy: In pregnant animals, rivastigmine and/or metabolites crossed the placenta. It is not known if this occurs in humans. In animal studies, rivastigmine was not teratogenic. However, the safety of Exelon in human pregnancy has not been established, and it should only be given to pregnant women if the potential benefit outweighs the potential risk for the foetus.
Breast-feeding: In animals, rivastigmine and/or metabolites were excreted in breast milk. It is not known if Exelon is excreted into human milk, and patients on Exelon should therefore not breast-feed.
Fertility: In male and female rats, no adverse effects of rivastigmine were observed on fertility or reproductive performance of either the parent generation or the offspring of the parents (see Pharmacology: Toxicology: NON-CLINICAL SAFETY DATA under Actions). There is no information available on the effects of rivastigmine on human fertility.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in